<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544115</url>
  </required_header>
  <id_info>
    <org_study_id>01089</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-01089</secondary_id>
    <secondary_id>01089</secondary_id>
    <secondary_id>CDR0000566376</secondary_id>
    <nct_id>NCT00544115</nct_id>
  </id_info>
  <brief_title>Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders</brief_title>
  <official_title>A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell
      transplant helps stop the growth of cancer or abnormal cells. It also helps stop the
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
      from a donor are infused into the patient they may help the patient's bone marrow make stem
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells
      from a donor can make an immune response against the body's normal cells. Giving tacrolimus,
      methotrexate, cyclosporine, mycophenolate mofetil, and sirolimus before and after transplant
      may stop this from happening.

      PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant works
      in treating patients with advanced hematologic cancer or other disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate hematopoietic recovery, using neutrophil and platelet engraftment as the
           primary criterion, in patients with advanced hematologic malignancies or other disorders
           undergoing allogeneic peripheral blood stem cell (PBSC) transplantation from matched
           unrelated donors.

        -  To evaluate the incidence of acute and chronic graft-versus-host-disease (GVHD) in
           patients undergoing allogeneic PBSC transplantation from matched unrelated donors.

      Secondary

        -  To evaluate the impact of HLA class I and class II allele-matching on the incidence of
           GVHD and on the survival outcome of these patients.

        -  To evaluate overall survival, disease-free survival, and relapse in these patients.

      OUTLINE: Patients are stratified according to type of conditioning regimen (myeloablative vs
      reduced-intensity myeloablative). Patients are assigned to a conditioning regimen according
      to diagnosis, age, disease status, prior radiotherapy, and prior autologous stem cell
      transplantation.

        -  Conditioning regimen:

             -  Regimen I: Patients undergo total body irradiation (TBI) on days -7 to -4 and
                receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive
                cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.

             -  Regimen II: Patients receive busulfan IV over 2 hours once on day -8 and then every
                6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and
                -2.

             -  Regimen III: Patients undergo TBI on days -7 to -4 and receive etoposide IV on day
                -3.

             -  Regimen IV: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to
                -3 and melphalan IV on day -2.

             -  Regimen V: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to
                -2 and undergo TBI on day 0.

             -  Regimen VI: Patients receive busulfan IV over 3 hours and fludarabine phosphate IV
                over 30 minutes on days -5 to -2.

        -  Allogeneic peripheral blood stem cell (PBSC) transplantation: All patients undergo
           allogeneic PBSC transplantation on day 0.

        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive one of the following GVHD
           prophylaxis regimens:

             -  Regimen A: Patients receive tacrolimus IV or orally on days -1 to 180 and
                methotrexate IV on days 1, 3, 6, and 11.

             -  Regimen B: Patients receive cyclosporine IV or orally twice daily on days -1 to
                180, mycophenolate mofetil IV over 2 hours or orally twice daily on days 0-27, and
                methotrexate IV on days 1, 3, and 6.

             -  Regimen C: Patients receive tacrolimus IV continuously or orally, and oral
                sirolimus beginning on day -3. Patients also receive methotrexate IV on days 1, 3,
                and 6.

      After completion of study therapy, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil and platelet engraftment</measure>
    <time_frame>180 days post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute and chronic graft-versus-host disease (GVHD)</measure>
    <time_frame>1 year post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of HLA class I and class II allele-matching on the incidence of GVHD and on the survival outcome</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>At the time of relapse post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <arm_group>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen VI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Regimen III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>Regimen IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen II</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen IV</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
    <arm_group_label>Regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <arm_group_label>Regimen I</arm_group_label>
    <arm_group_label>Regimen III</arm_group_label>
    <arm_group_label>Regimen V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following:

               -  Acute lymphocytic leukemia (ALL), meeting one of the following criteria:

                    -  In first relapse or beyond

                    -  High-risk ALL, defined by any of the following:

                         -  Hypoploidy (≤ 44 chromosomes)

                         -  Pseudodiploidy with translocations or molecular evidence of t(9;22),
                            11q23, or t(8;14), excluding B-cell ALL

                         -  Elevated WBC at presentation (WBC &gt; 20,000/mm³ [for patients &gt; 18 years
                            of age]; WBC &gt; 200,000/mm³ [for patients 12-18 years of age])

               -  Acute myeloid leukemia (AML), meeting one of the following criteria:

                    -  In first complete remission

                    -  Failed to achieve remission

                    -  In first relapse or beyond

                    -  Secondary AML (&gt; 30% blasts in marrow aspirate)

                         -  Should receive induction chemotherapy to obtain remission, if possible,
                            before transplant

               -  Chronic myelogenous leukemia, meeting one of the following criteria:

                    -  In first or second chronic phase or accelerated phase

                    -  In blast crisis, defined as &gt; 30% promyelocytes plus blasts in the bone
                       marrow

               -  Myelodysplastic syndromes, including any of the following:

                    -  Refractory anemia with excess blasts (RAEB)

                    -  Chronic myelomonocytic leukemia

                    -  RAEB in transformation

               -  Refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma,
                  or multiple myeloma

                    -  Received and failed front-line therapy, high-dose therapy and autologous
                       stem cell transplantation, or salvage therapy

               -  Myeloproliferative disorders/myelofibrosis may be allowed on a case by case basis

               -  Severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, or any other
                  hematologic disorder requiring transplantation

          -  Patients &gt; 55 years of age with hematologic diseases treatable by allogeneic stem cell
             transplantation who are not eligible for IRB 99190 are eligible

          -  No uncontrolled CNS involvement of disease

          -  No matched (6/6) related donor available

          -  HLA-identical unrelated donor available

               -  HLA-phenotypically identical for HLA-A and HLA-B alleles and identical for DRB1
                  alleles by DNA typing for both class I and class II antigens

                    -  Allele mismatch for HLA class I (i.e., B 2701 vs B 2702) allowed if no
                       alternative donors

                    -  Allele mismatch for class II (i.e., DRB1 0401 vs 0402) or minor mismatch for
                       class I cross reactive group (CREG) (i.e., A 2 vs A 28) allowed in patients
                       ≤ 35 years of age requiring urgent transplant

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 50-100%

          -  Life expectancy &gt; 8 weeks

          -  LVEF ≥ 45% at rest

          -  AST ≤ 2 times normal (unless liver function abnormality is due to underlying disease)

          -  Total bilirubin &lt; 1.5 times normal (unless liver function abnormality is due to
             underlying disease)

          -  Creatinine ≤ 1.5 times normal OR creatinine clearance ≥ 60 mL/min

          -  DLCO ≥ 40% of predicted (corrected for hemoglobin)

          -  No coexisting medical problem that would significantly increase the risk of the
             transplant procedure

          -  HIV negative

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auayporn P. Nademanee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>paroxysmal nocturnal hemoglobinuria</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

